CSPC Pharmaceutical Group Limited (HKG:1093)

Market Cap	82.78B +26.8%
Revenue (ttm)	28.94B -5.9%
Net Income	3.71B -22.2%
EPS	0.33 -20.6%
Shares Out	11.43B
PE Ratio	22.27
Forward PE	10.71
Dividend	0.29 (4.01%)
Ex-Dividend Date	Jun 24, 2026

Volume	101,695,582
Open	7.06
Previous Close	7.24
Day's Range	6.98 - 7.22
52-Week Range	6.64 - 11.63
Beta	0.73
Analysts	Buy
Price Target	11.49 (+62.06%)
Earnings Date	May 27, 2026

About CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma,...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 19,700
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1093

Financial Performance

In 2025, CSPC Pharmaceutical Group's revenue was 26.01 billion, a decrease of -10.35% compared to the previous year's 29.01 billion. Earnings were 3.88 billion, a decrease of -10.30%.

Financial numbers in CNY

Analyst Summary

According to 24 analysts, the average rating for 1093 stock is "Buy." The 12-month stock price target is $11.49, which is an increase of 62.06% from the latest price.

Price Target

$11.49

(62.06% upside)

Analyst Consensus: Buy